What is the Impact of Serum Molecular Markers on the Diagnosis of Thyroid Cancers? A Comparison of Serum Molecular Markers with Invasive Biopsy Methods
Asian Journal of Research and Reports in Endocrinology,
Background: Tissue molecular markers have taken their place as an effective, invasive method in the diagnosis of thyroid cancers. However, if the superiority of serum molecular markers to invasive diagnostic methods as a noninvasive method can be proven, it will have a great impact on the diagnostic approach and screening programs for thyroid nodules.
Aim: The aim in this study is to investigate the effectiveness of serum molecular markers compared to invasive methods in the diagnosis of thyroid cancers.
Methods: In our study, results obtained in publications in which serum molecular markers were used in the diagnosis of thyroid cancers and absolute sensitivity was measured were compared with the absolute sensitivity rates obtained in cases where invasive methods such as fine needle aspiration biopsy and core needle biopsy were used. The results were evaluated statistically.
Results: In cases where serum molecular markers were used in the diagnosis of thyroid cancer, absolute sensitivity rates were found to be statistically significantly higher than invasive methods.
Conclusion: According to the results we have obtained, molecular markers in serum are a noninvasive method that can be used safely in thyroid cancer screening, definitive diagnosis and follow-up. Although it is a noninvasive method, its definitive diagnosis rates are higher compared to methods such as invasive fine needle aspiration biopsy and core needle biopsy.
Therefore, in the near future, it is likely to take a higher priority in the diagnostic approach and screening programs for thyroid nodules.
- Thyroid cancer
- diagnostic methods
- molecular markers
- fine needle aspiration biopsy
- core needle biopsy
How to Cite
Acar H. Current diagnostic approach on thyroid nodules. Academic Studies in Health Sciences-II – gecekitapligi.com. 2020;Chapter 32:48-50.
Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, et al: MicroRNA-based molecular classification of papillary thyroid carcinoma. Int.J Oncol. 2017;1767-1777.
Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W. The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020;271(3).
Liu B, Liang J, Zheng Y, Xie X, Huang G, Zhou L, et al. Two-dimensional shear wave elastography as promising diagnostic tool for predicting malignant thyroid nodules: A prospective single-centre experience. Eur Radiol. 2015;25:624-634.
Horvath E, Silva CF, Majlis S, Rodriguez I, Skoknic V, Castro A, et al. Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting And Data System) classification: Results in surgically resected thyroid nodules. Eur Radiol. 2016;27:2619-2628.
Nabhan F, Ringel MD. Thyroid nodules and cancer management guidelines: Comparisons and controversies. Endocr Relat Cancer. 2017;24(2):R13-R26.
Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hemat. 2019;141:36-42.
Ghafouri-Fard S, Shirvani-FarsaniZ,Tahari M: The role of microRNAs in the pathogenesis of thyroidcancer. Non-coding RNA Res. 2020;5(3):88-98.
Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metab. 2014;99(11):4190–4198.
Lee JC, Zhao JT, Clifton RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA‐222 and MicroRNA‐146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119(24):4358-4365.
Rezai M, Khamanah AM, Zarghami N, Vosoughi A, Hashemzadeh S. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules. BMC Cancer. 2019;19:690.
Li H, Lou Y, Wang L. Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma. Plos ONE. 2015;10(7):e0132403.
Seningen JL, Nassar A, Henry MR. Correlation of thyroid nodule fine‐needle aspiration cytology with corresponding histology at Mayo Clinic, 2001–2007: An institutional experience of 1,945 cases. Diagn Cytopathol. 2012;40(S1):27-32.
Lew JI, Snyder A, Sanchez MBA, Solorzano CC. Fine needle aspiration of the thyroid: Correlation with final histopathology in a surgical series of 797 patients. J Am Coll Surgeons. 2013;(1):188-194.
Paja M, Cura JLD, Zabala R, Korta I, Ugalde A, Lopez JI. Core-needle biopsy in thyroid nodules: Performance, accuracy, and complications. Eur Radiol. 2019;29(9):4889-4896.
Sung JY, Na DG, Kim KS, Yoo H, Lee H,Kim J, et al. Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. Eur Radiol. 2012;22(7):1564-1572.
Ye M, Hou H, Shen M, Dong S, Zhang T. Circular RNA circFOXM1 plays a role in papillary thyroid carcinoma by sponging miR-1179 and regulating HMGB1 expression. Mol Ther-Nucl Acids. 2019;20(19):741-750.
Zhang H, Ma XP, Li X, Deng FS. Circular RNA circ_0067934 exhaustion expedites cell apoptosis and represses cell proliferation, migration and invasion in thyroid cancer via sponging miR-1304 and regulating CXCR1 expression. Eur Rev Med Pharmaco. 2019;23(24):10851-10866.
Huang BL, Chabot JA, Lee JA, Kuo JH. A stepwise analysis of the diagnostic algorithm for the prediction of malignancy in thyroid nodules. Surgery. 2020;167(1):28-33.
Mais DD, Crothers BA, Davey DD, Natale KE, Nayar R, Souers RJ. Trends in thyroid fine-needle aspiration cytology practices: Results from a college of american pathologists 2016 practice survey. Arch Pathol Lab Med. 2019;143(11):1364-1372.
Ke J, Jianyong L, Ying L, Genpeng L, Linlin S, Zhihui L, et al. The use of the Bethesda system for reporting thyroid cytopathology in a chinese population: An analysis of 13 351 specimens. Diagn Cytopathol. 2019;47(9):876-880.
Jack GA, Scot BS, Aronson MD, Mukamal KJ, Oshin A, Hennessey JV. Nondiagnostic fine-needle aspiration biopsy of thyroid nodules: Outcomes and determinants. Thyroid. 2020;30(7):992-998.
Hayashi T, Hirokawa M, Higuchi M, Kudo T, Ito Y, Miyauchi A. Needle tract implantation following fine-needle aspiration of thyroid cancer. World J Surg. 2020;44:378-384.
Kini SR. Post‐fine‐needle biopsy infarction of thyroid neoplasms: A review of 28 cases. Diagn Cytopathol. 1996;15:211-220.
Gómez-Pérez AM, Cornejo Pareja IM, García Alemán J, Coín Aragüez L, Sebastián OA, Alcaide TJ, et al. New molecular biomarkers in differentiated thyroid carcinoma: Impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease. Clin Endocr. 2019;91(1):187-194.
Shabani N, Sheikholeslami S, Paryan M, Yeganeh MZ, Tavangar SM, Azizi F, et al. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. J Cell Physiol. 2020;235(2):1366-1373.
Fanfone D, Stanicki D, Nonclercq D, Port M, Elst LV, Laurent S, et al. Molecular imaging of galectin-1 expression as a biomarker of papillary thyroid cancer by using peptide-functionalized imaging probes. Biology (Basel). 2020;9(53):1-25.
Makki FM, Taylor SM, Shahnavaz A, Leslie A, Gallant J, Douglas S, et al. Serum biomarkers of papillary thyroid cancer. J Otolaryngol-Head N. 2013;42(16):1-10.
Abooshahab R, Gholami M, Sanoie M, Azizi F, Hedayati M. Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation. Endocrine. 2019;65:1-14.
Bircan R, Gözü HI, Ulu E, Sarıkaya Ş, Gül AE, Şirin DY, et al. The mitochondrial DNA control region might have useful diagnostic and prognostic biomarkers for thyroid tumors. Exp Clin Endocr Diab. 2019;127(7):423-436.
Sedaghati M, Kebebew E. Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol. 2019;26(5):275-281.
Li J, Vasilyeva E, Wiseman SM. Beyond immunohistochemistry and immunocytochemistry: A current perspective on galectin-3 and thyroid cancer. Expert Rev Anticanc. 2019;19(12):1017-1027.
Oloomi M, Moazzezy N, Bouzari S. Comparing blood versus tissue-based biomarkers expression in breast cancer patients. Heliyon. 2020;6(4):1-7.
Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocr Metab. 2011;96(11):E1719-1726.
Nylen C, Mechera R, Marechal-Ross I, Tsang V: Molecular markers guiding thyroid cancer management. Cancers. 2020;12(8).
Rosignolo F, Sponziello M, Giacomelli L, Russo D, PecceV, Biffoni M, et al: Identification of thyroid-associated serum microRNA profiles and their potential use in thyroid cancer follow-up. J Endocr Soc. 2017;1(1):3-13.
Mahmoudian-Sani M, Mehri-Ghahfarrokhi A, Asadi-Samani M, Mobini R: Serum miRNAs as biomarkers for the diagnosis and prognosis of thyroid cancer: A comprehensive review of the literature. Eur Thyroid J. 2017;6(4):171-177.
Fan CM, Wang JP, Tang YY, Zhao J, He SY, Xiong F, et al: circMAN1A2 could serve as a novel serum biomarker for malignant tumors. Cancer Sci. 2019;110(7):2180-2188.
Pilli T, Cantara S, Marzocchi C, Cardinale S, Santini C, Cevenini G, et al: Diagnostic value of circulating microRNA-95 and -190 in the differential diagnosis of thyroid nodules: A validation study in 1000 consecutive patients. Thyroid. 2017;27(8):10.
Zhang Y, Pan I, Xu D, Yang Z, Sun I, Sun L, et al. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma. Oncol Rep. 2018;40(6):3611-3624.
Abstract View: 60 times
PDF Download: 45 times